Future Partner

This SME should preferably be a small biotech company with an interest in the development of new therapies based on knowledge of molecular pathogenesis of rheumatoid arthritis or myositis. Recruitment of this partner will start in time to allow this partner to be included after the first 18 months. The EU rules will be followed in the recruitment of this new partner.